The efficacy of 2,3-dimercaptopropanol and D-penicillamine on methyl mercury induced neurological signs and weight loss

In order to test the effectiveness of complexing therapy on methyl mercury induced neurotoxicity, female rats were treated for five days with either 2,3-dimercaptopropanol (BAL) or D-penicillamine (DPA) beginning 1 or 12 days after the final dose of methyl mercury hydroxide (MMOH). MMOH was administered orally at a dose of 13.3 mg/kg once each day for 3 successive days. BAL, dissolved in peanut oil, was administered sc in a dose of 30 mg/kg twice each treatment day. DPA was dissolved in water and administered sc in a dose of 1200 mg/kg once each treatment day. Therapy begun 1 day after the last MMOH administration was prior to the appearance of toxic signs but therapy begun 12 days later was after signs had developed. The ability of BAL or DPA therapy to alter the distribution of radio-labelled (²⁰³Hg) MMOH was determined. Both DPA and BAL significantly reduced tissue concentrations of mercury when administered beginning 1 day after MMOH, but only DPA was effective in removing mercury from tissues when treatment was begun 12 days after the last dose of MMOH. In a separate experiment when either BAL or DPA therapy was initiated as above 1 day after the last dose of MMOH, the appearance of neurological signs of toxicity was prevented and weight loss was reversed. When therapy was initiated the twelfh day after the last MMOH dose, neither BAL nor DPA was effective in reversing either neurotoxic signs or weight loss. Therefore, therapy is ineffective in reversing neurological signs if it is delayed too long after MMOH administration, even though it is effective in reducing tissue mercury levels.